Sarepta Therapeutics’ (SRPT) “Underperform” Rating Reaffirmed at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “underperform” rating reissued by Needham & Company LLC in a research note issued on Thursday,Benzinga reports.

Other research analysts have also issued research reports about the stock. Royal Bank Of Canada upped their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Mizuho upped their price target on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, March 12th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, March 2nd. Finally, Oppenheimer restated an “outperform” rating and issued a $37.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $32.15.

Sarepta Therapeutics Trading Up 35.0%

NASDAQ:SRPT opened at $23.77 on Thursday. The stock has a market cap of $2.50 billion, a PE ratio of -2.82, a price-to-earnings-growth ratio of 0.28 and a beta of 0.42. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $74.40. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The stock’s 50-day moving average is $18.70 and its two-hundred day moving average is $19.96.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The company had revenue of $442.93 million during the quarter, compared to analysts’ expectations of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.Sarepta Therapeutics’s revenue for the quarter was down 32.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 earnings per share. As a group, equities research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. This represents a 80.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. boosted its holdings in Sarepta Therapeutics by 98.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 2,034 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Sarepta Therapeutics by 340.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 95,752 shares of the biotechnology company’s stock valued at $2,061,000 after buying an additional 74,027 shares in the last quarter. EP Wealth Advisors LLC bought a new position in Sarepta Therapeutics during the fourth quarter valued at about $213,000. Mackenzie Financial Corp lifted its position in shares of Sarepta Therapeutics by 17.1% in the fourth quarter. Mackenzie Financial Corp now owns 58,042 shares of the biotechnology company’s stock worth $1,245,000 after buying an additional 8,494 shares during the last quarter. Finally, Virtus Investment Advisers LLC lifted its position in shares of Sarepta Therapeutics by 166.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 31,741 shares of the biotechnology company’s stock worth $683,000 after buying an additional 19,830 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Key Stories Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA data show dose‑dependent muscle exposure, biomarker effects and good tolerability for SRP‑1001 and SRP‑1003 — the core trigger for the sharp rally as these programs open a new pipeline opportunity beyond Sarepta’s exon‑skipping assets. Sarepta Announces First Clinical Data (Business Wire)
• Positive Sentiment: Morgan Stanley raised its price target (~25% hike reported in press coverage) after the trial readout, which helped validate the market reaction and supported increased buy interest. SRPT Skyrockets on Morgan Stanley PT Hike (InsiderMonkey)
• Positive Sentiment: Unusually heavy options activity (notably call buying) signals speculative/leveraged bullish positioning that can amplify short‑term upside. (Market trading data reported by market outlets.)
• Neutral Sentiment: Sarepta hosted a webcast and conference call to present the data (timing and slides add transparency); follow‑on data and larger cohorts will determine durability and clinical effect size. Sarepta Announces First Clinical Data (Yahoo Finance)
• Neutral Sentiment: Market commentary and valuation pieces are reassessing Sarepta as an siRNA‑enabled rare disease company — that raises upside potential but also pushes valuation questions; investors should watch analyst revisions. Assessing Sarepta Valuation (Yahoo Finance)
• Negative Sentiment: Near‑term fundamentals remain mixed: Sarepta reported a large EPS miss in February and still shows negative margins/ROE — the company needs durable clinical wins and clear commercialization paths to justify higher multiples.
• Negative Sentiment: Some Wall Street voices remain cautious, noting the data are early, small‑sample and not yet proof of clinical benefit — skepticism could cap gains if follow‑up data are slower or weaker than hoped. Wall Street Not Wholly Convinced (MSN)

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.